Hansoh Pharmaceutical Group Company Limited
翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025

The board (the "**Board**") of directors (the "**Directors**") of Hansoh Pharmaceutical Group Company Limited (the "**Company**") is pleased to announce the consolidated annual results of the Company and its subsidiaries (collectively, the "**Group**") for the year ended December 31, 2025 (the "**Reporting Period**"), together with the comparative figures for the corresponding period in 2024.

In this announcement, "we", "us" and "our" refer to the Company and the Group, depending on the context.

FINANCIAL HIGHLIGHTS

For the year ended December 31, 2025, the Group recorded the following audited results:

- Revenue was approximately RMB15,028 million, representing an increase of approximately 22.6% compared with the corresponding period of the previous year;
- Revenue of innovative medicines and collaborative products amounted to approximately RMB12,354 million, representing an increase of approximately 30.4% compared with the corresponding period of the previous year, and its proportion of total revenue increased to approximately 82.2%;
- R&D expenditure was approximately RMB3,358 million, representing an increase of approximately 24.3% compared with the corresponding period of the previous year, and accounted for approximately 22.3% of the revenue;
- Profit for the year was approximately RMB5,555 million, representing an increase of approximately 27.1% compared with the corresponding period of the previous year;
- Basic earnings per share was approximately RMB0.93, representing an increase of approximately 26.4% compared with the corresponding period of the previous year.

The increase in revenue, profit for the year and basic earnings per share during the Reporting Period was primarily due to the increase in revenue of innovative medicines and collaborative products.

The Board recommends a final dividend of HK$20.00 cents per share for the year ended December 31, 2025, subject to the approval of the Shareholders at the AGM. Together with an interim dividend, the full-year dividend for 2025 amounted to HK$43.16 cents per share.

CORPORATE OVERVIEW

The Company is a leading innovation-driven pharmaceutical enterprise in the People's Republic of China ("**China**" or "**PRC**"). With the mission of "continuous innovation for better life", the Company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system ("**CNS**"), metabolism and immunology. The Company has launched seven innovative medicines that generate product sales in China, forming a rich product pipeline. For the year ended December 31, 2025, the revenue of innovative medicines and collaborative products amounted to approximately RMB12,354 million and accounted for approximately 82.2% of the revenue, becoming a core driver for sustainable growth of the Group's performance.

The major achievements during the Reporting Period were as follows:

In January 2025, Risvutatug Rezetecan (Company code HS-20093/collaborator code GSK5764227), the Group's self-developed B7-H3-targeted antibody-drug conjugate ("**ADC**"), received the U.S. Food and Drug Administration (the "**FDA**") Breakthrough Therapy Designation ("**BTD**"), and was evaluated for the treatment of adult patients with relapsed or refractory osteosarcoma (bone cancer) who have progressed on at least two prior lines of therapy.

In February 2025, the National Medical Products Administration (國家藥品監督管理局) (the "**NMPA**") of China listed HS-20093 for injection as a Breakthrough-Therapy-Designated Drug, with the proposed indication for the treatment of patients with osteosarcoma who have progressed on at least two prior lines of therapy.

In February 2025, based on the positive results from the global pivotal phase III MITIGATE trial on XINYUE (昕越®) (Inebilizumab Injection), the treatment of immunoglobulin G4-related disease ("**IgG4-RD**") of the product has been included in the Priority Review and Approval Procedure by the NMPA. In March 2025, Biologics License Application ("**BLA**") of this indication was accepted by the NMPA. In August 2025, XINYUE was granted drug registration approval by the NMPA for the treatment of adult patients with IgG4-RD. This is the second indication of XINYUE which has been approved.

In February 2025, the Category 1 small molecule Bruton's tyrosine kinase inhibitor ("**BTKi**") HS-10561 capsules, which is jointly developed by the Group and Guangzhou Lupeng Pharmaceutical Co., Ltd.* (廣州麓鵬製藥有限公司) ("**Lupeng Pharma**"), obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for chronic spontaneous urticaria.

In March 2025, Ameile (阿美樂®) (Aumolertinib Mesylate Tablets), an innovative medicine of the Group, was granted drug registration approval for its third indication by the NMPA for the treatment of patients with locally advanced, unresectable non-small cell lung cancer ("**NSCLC**") whose disease has not progressed following definitive platinum-based chemoradiotherapy whose tumors have epidermal growth factor receptor ("**EGFR**") exon 19 deletions or exon 21 (L858R) substitute mutations.

In April 2025, the Group's ADC targeting EGFR/c-MET, HS-20122 for injection, obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for advanced solid tumors, including NSCLC, head and neck squamous cell carcinoma, or colorectal cancer.

In April 2025, HS-20108 for injection, self-developed by the Group, obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for advanced solid tumors such as small cell lung cancer ("**SCLC**") and neuroendocrine tumors.

In April 2025, HS-10529 tablets, a small molecule drug targeting KRAS G12D self-developed by the Group, obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for advanced solid tumors (pancreatic cancer, colorectal cancer, NSCLC, etc.) with KRAS G12D mutations.

In April 2025, the NMPA listed HS-20093 as a Breakthrough-Therapy-Designated Drug, with the proposed indication for locally advanced or metastatic non-squamous NSCLC without driver mutations, progressed or recurred following platinum-based chemotherapy.

In May 2025, the NMPA listed HS-20089 for injection, the Group's self-developed B7-H4-targeted ADC, as a Breakthrough-Therapy-Designated Drug, with the proposed indication for platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer patients.

In May 2025, Ameile was granted drug registration approval for its fourth indication by the NMPA for the treatment of adult patients with stage II to IIIB NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutations, and who have undergone tumor resection with or without prior adjuvant chemotherapy as determined by their physician.

In May 2025, the Group's self-developed HS-20118 tablets obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for moderate to severe plaque psoriasis.

In May 2025, the Group's self-developed HS-10542 capsules obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for paroxysmal nocturnal hemoglobinuria ("**PNH**") and immunoglobulin A nephropathy ("**IgAN**").

In May 2025, the Group's self-developed HS-10510 tablets obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for primary hypercholesterolemia and mixed dyslipidemia.

In May 2025, the third BLA of XINYUE was accepted by the NMPA, which is for the treatment of generalized myasthenia gravis ("**gMG**") in adult patients.

In June 2025, the Group entered into a license agreement with Regeneron Pharmaceuticals, Inc. ("**Regeneron**"), pursuant to which the Group has granted Regeneron an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong and Macau) to develop, manufacture and commercialize HS-20094, an investigational dual glucagon-like peptide-1 ("**GLP-1**")/ glucose-dependent insulinotropic polypeptide ("**GIP**") receptor agonist.

In June 2025, Aumolertinib Mesylate Tablets (overseas trade name: Aumseqa®), the Group's innovative medicine, was approved by the Medicines and Healthcare Products Regulatory Agency in the UK ("**MHRA**"), which as monotherapy is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations, and the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

In October 2025, the Group entered into a license agreement with F. Hoffmann-La Roche Ltd ("**Roche**"), pursuant to which, the Group granted Roche an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, Macau and Taiwan) to develop, manufacture and commercialize HS-20110, an investigational CDH17-targeting ADC.

In October 2025, the New Drug Application ("**NDA**") of the Group's innovative medicine HS-10365 capsules, a potent and selective rearranged during transfection ("**RET**") inhibitor, was accepted by the NMPA for the treatment of adult patients with RET fusion-positive locally advanced or metastatic NSCLC.

In December 2025, the third and the fourth indications of Ameile have been newly added to the 2025 National Reimbursement Drug List ("**NRDL**"). Additionally, all indications of the Group's innovative medicine, Pegmolesatide Injection (trade name: Saint Luolai 聖羅萊®) and Tenofovir Amibufenamide Tablets (trade name: Hengmu 恒沐®) have been renewed in the 2025 NRDL.

In December 2025, the Group entered into an exclusive license, collaboration and distribution agreement with Glenmark Specialty S.A. ("**Glenmark**"), pursuant to which, the Group has granted Glenmark an exclusive license to develop and commercialize Aumolertinib across its licensed territories: the Middle East and Africa, Southeast and South Asia, Australia, New Zealand, Russia/CIS and a few selected Caribbean countries covered by the license agreement.

In December 2025, the Group entered into a license agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("**Hengrui**"), pursuant to which, the Group was granted an exclusive license to develop, manufacture and commercialize HS-10568 (collaborator code SHR6508), an investigational calcium-sensing receptor (CaSR) allosteric modulator, in the PRC (excluding Hong Kong, Macau and Taiwan).

The Group has improved steadily in environmental, social and governance ("**ESG**") aspects. As of the date of this announcement, the MSCI ESG rating of the Group was upgraded to the highest level of AAA, and the Group was again selected for inclusion in the *Sustainability Yearbook (Global Edition) 2026* and the *Sustainability Yearbook (China Edition) 2025* published by S&P Global ("**S&P**"), and ranked among the top 1% in the Chinese pharmaceutical industry, as well as received a B rating for climate change and a B rating for water safety in the 2025 corporate environmental information disclosure rating by Carbon Disclosure Project (CDP), a globally authoritative environmental information disclosure platform, maintaining a leading position among pharmaceutical enterprises in the PRC. It not only indicates the Company's past achievements in the ESG field, but also represents our long-term commitment and strategic plan for sustainable development.

The website of the Group: **www.hspharm.com/**

MANAGEMENT DISCUSSION AND ANALYSIS

Industry Review

In 2025, China's innovative medicine industry entered a new development stage of "equal emphasis on quality and efficiency". Its development pathway has gradually shifted from a previously research and development ("**R&D**") investment-driven model to a model driven by clinical value prioritization and commercialization efficiency. On the one hand, the efficiency of the review and approval process for domestic innovative medicines has continued to improve, the accessibility of innovative medicines has been continuously enhanced, and coupled with the multi-level medical payment system becoming increasingly mature, a solid foundation has been laid for high-quality industry development. On the other hand, industry competition has continued to intensify, with a rising concentration of projects in core therapeutic areas, which has imposed higher requirements on enterprises in terms of areas including differentiated clinical positioning, real-world evidence accumulation, commercialization implementation capabilities and cost control efficiency.

As the overall innovation capacity and industry influence of the China innovative biopharmaceutical sector have steadily improved, a number of innovative assets with differentiated potential have already demonstrated cross-border development value and industrial synergy advantages as early as the R&D stage, driving the industry into a new phase of accelerated global value realization. In 2025, the activity of China's innovative pharmaceutical companies in cross-border licensing and cooperation increased significantly, with license-out transactions witnessing explosive growth. The transaction amount accounted for approximately 50% of the total global pharmaceutical transaction amount, reflecting the growing global recognition of China's innovative capabilities within the international pharmaceutical value chain, as well as the further enhancement of the value and the increasing global pricing influence of China's innovative assets.

Business Highlights

For the year ended December 31, 2025, the Group recorded revenue of approximately RMB15,028 million, representing an increase of approximately 22.6% compared with the corresponding period of the previous year; profit for the year of approximately RMB5,555 million, representing an increase of approximately 27.1% compared with the corresponding period of the previous year; basic earnings per share of approximately RMB0.93, representing an increase of approximately 26.4% compared with the corresponding period of the previous year; revenue of innovative medicines and collaborative products amounted to approximately RMB12,354 million, and its proportion of total revenue increased to approximately 82.2%.

We generate our revenue primarily from sales of pharmaceutical products. Our main products are concentrated in the main therapeutic areas on which the Group strategically focuses, including oncology, anti-infectives, CNS, metabolic and other diseases. The increase in revenue, profit for the year and basic earnings per share during the Reporting Period was primarily due to the increase in the revenue of innovative medicines and collaborative products.

For the year ended December 31, 2025, the revenue and product portfolio of our therapeutic areas are as follows:

Therapeutic Area	Product Portfolio
Oncology (revenue amounted to approximately RMB9,974 million, accounting for approximately 66.4% of the total revenue)	Innovative medicine Ameile (Aumolertinib Mesylate Tablets), innovative medicine Hansoh Xinfu (Flumatinib Mesylate Tablets), Pulaile (Pemetrexed Disodium for Injection), Pulaitan (Enzalutamide Soft Capsules) and Xinwei (Imatinib Mesylate Tablets), etc.
Anti-infectives (revenue amounted to approximately RMB1,586 million, accounting for approximately 10.6% of the total revenue)	Innovative medicine Hengmu (Tenofovir Amibufenamide Tablets) and Hengsen (Micafungin Sodium for Injection), etc.
CNS (revenue amounted to approximately RMB1,310 million, accounting for approximately 8.7% of the total revenue)	Innovative medicine XINYUE (Inebilizumab Injection), Ameining (Agomelatine Tablets), Ailanning (Paliperidone Extended-Release Tablets) and Oulanning (Olanzapine Tablets/Orally Disintegrating Tablets/Oral Soluble Film), etc.
Metabolic and other diseases (revenue amounted to approximately RMB2,158 million, accounting for approximately 14.3% of the total revenue)	Innovative medicine Fulaimei (PEG-Loxenatide for Injection), innovative medicine Saint Luolai (Pegmolesatide Injection), Fulaidi (Repaglinide Tablets) and Punuoan (Ambrisentan Tablets), etc.

Innovative Medicine Products

Ameile (阿美樂®)

Ameile (Aumolertinib Mesylate Tablets) is the first original third-generation EGFR-tyrosine kinase inhibitor ("**TKI**") innovative medicine in China self-developed by the Group. In March 2020, it was approved for the treatment of patients with locally advanced or metastatic NSCLC with T790M mutation positive, who have progressed on or after EGFR-TKI therapy; in December 2021, it was approved as the first-line treatment for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutation positive.

Ameile is continuously expanding its indications. As of the date of this announcement, three new indications of Ameile have been approved by the NMPA, with details as follows:

In March 2025, the third indication of Ameile was approved for the treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following definitive platinum-based chemoradiotherapy whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutations.

In May 2025, the fourth indication of Ameile was approved for the treatment of adult patients with stage II to IIIB NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutations, and who have undergone tumor resection with or without prior adjuvant chemotherapy as determined by their physician.

In January 2026, the fifth indication of Ameile was approved, in combination with pemetrexed and platinum based chemotherapy to be used as the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) mutations.

Currently, the first to fourth indications of Ameile have been included in the NRDL, continuously enhancing patient accessibility.

Ameile continues to strengthen its evidence base. As of the date of this announcement, Ameile has been recommended as Class I or Preferred by eight national diagnosis and treatment guidelines, including the *Chinese Society of Clinical Oncology ("**CSCO**") Guidelines for the treatment of Non-small Cell Lung Cancer (2025 Edition)** (《中國臨床腫瘤學會非小細胞肺癌診療指南(2025 版)》). During the Reporting Period, 33 academic achievements of Ameile were selected for authoritative conferences or top academic journals such as the American Association for Cancer Research ("**AACR**"), the European Lung Cancer Congress (ELCC), the American Society of Clinical Oncology (ASCO) Annual Meeting, the World Conference on Lung Cancer (WCLC), the CSCO Annual Meeting and *The Lancet Oncology*.

In April 2025, two phase III pivotal clinical studies of Ameile were selected for oral presentations at the 2025 AACR Annual Meeting, namely the ARTS study (adjuvant treatment of NSCLC post-surgery) and the AENEAS2 study (in combination with chemotherapy as first-line therapy for advanced NSCLC). ARTS study data shows that for patients with stage II to IIIB NSCLC whose tumors have EGFR mutations and who have undergone complete tumor resection, following Ameile adjuvant therapy as appropriate, their disease-free survival ("**DFS**") can be significantly improved with HR of 0.17. The investigator-assessed 2-year DFS rate was as high as 90.2%, and the safety profile was manageable on the whole. The AENEAS2 study data shows that for patients with locally advanced or metastatic NSCLC whose tumors have EGFR-sensitive mutations, progression-free survival (PFS) of the patients with Ameile in combination with chemotherapy as first line therapy has been significantly extended with HR of 0.47 as compared to monotherapy, suggesting that Ameile in combination with chemotherapy can reduce risks of disease progression or death by 53% as compared to monotherapy. Median progression-free survival (mPFS) has been extended to 28.9 months and objective response rate (ORR) was as high as 93.2%. No new safety risk has been identified.

As at the date of this announcement, Ameile has made additional global progress, including:

In June 2025, Ameile (overseas trade name: Aumseqa®) was approved in the UK by the MHRA as monotherapy, indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations, and the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

In December 2025, the Group entered into an exclusive license, collaboration and distribution agreement with Glenmark, pursuant to which, the Group has granted Glenmark an exclusive license to develop and commercialize Aumolertinib across its licensed territories: the Middle East and Africa, Southeast and South Asia, Australia, New Zealand, Russia/CIS and a few selected Caribbean countries covered by the license agreement. The Group will receive an upfront payment, followed by potential regulatory and commercial milestone payments possibly cumulating to over US$1 billion, in addition to tiered royalties on net sales in the licensed territories.

In February 2026, Ameile (overseas trade name: Aumseqa®) was approved in the European Union as monotherapy for: (i) the first-line treatment of adult patients with advanced NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations; and (ii) the treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC. The approval by the European Commission (EC) follows the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ("**EMA**").

Hansoh Xinfu (豪森昕福®)

Hansoh Xinfu (Flumatinib Mesylate Tablets) is the first original novel second-generation TKI for chronic myelogenous leukemia in China, which was approved in 2019. In 2020, Hansoh Xinfu was included in the NRDL for the first time and was successfully renewed in November 2024, and is currently within the term of the agreement. For the treatment of chronic myelogenous leukemia, based on results of existing clinical trials, compared with first-generation TKIs, Hansoh Xinfu achieved faster and deeper molecular remission (e.g. MMR, MR4.5), and compared to second-generation and other TKIs, it has comparable depth of remission and longer-lasting efficacy. Hansoh Xinfu also has favorable safety profile, with no specific adverse reactions (such as pleural effusion or cardiotoxicity) relating to the use of other second-generation BCR-ABL TKI treatments being found. Further, no adverse reactions (such as hypertension or elevated lipase) related to STAMP allosteric inhibitor treatment have been reported, and it has been adopted for long-term application by an increasing number of patients. Both the *Guidelines for the Diagnosis and Treatment of Chronic Myelogenous Leukemia (2022 Edition)** (《慢性髓性白血病診療指南(2022 年版)》) issued by the National Health Commission of the PRC and the *Guidelines for Diagnosis and Treatment of Malignant Hematologic Diseases (2025)** (《恶性血液病診療指南(2025)》) issued by the CSCO recommended Hansoh Xinfu as the first-line treatment of chronic myelogenous leukemia. The *Guideline for the Diagnosis and Treatment of Chronic Myeloid Leukemia in China (2025 Edition)** (《慢性髓細胞性白血病中國診斷與治療指南(2025年版)》) recommended Flumatinib for first-line and subsequent line switching treatment of chronic myelogenous leukemia.

During the Reporting Period, four clinical studies of Hansoh Xinfu were presented at the 30th European Hematology Association (EHA) Annual Congress and the 67th American Society of Hematology (ASH) Annual Meeting.

XINYUE (昕越®)

XINYUE (Inebilizumab Injection) is a targeted CD19 B-cell depleting antibody and the world's first humanized CD19 monoclonal antibody approved for the treatment of adult patients with anti-aquaporin-4 ("**AQP4**") antibody-positive neuromyelitis optica spectrum disorder ("**NMOSD**"). On May 24, 2019, the Group entered into a license agreement with Viela Bio Inc. (which was acquired by Horizon Therapeutics plc in 2021, and the latter was acquired by Amgen INC ("**Amgen**") in 2023) to obtain an exclusive license to develop and commercialize the product in Chinese Mainland, Hong Kong and Macau. On March 14, 2022, the product was approved by the NMPA in China and is indicated for the treatment of adult NMOSD patients who are AQP4 antibody positive. In January 2023, XINYUE was included in the NRDL for the first time and was successfully renewed in November 2024, and is currently within the term of the agreement.

In February 2025, based on the positive results of the global pivotal phase III MITIGATE trial on XINYUE, the new indication of the product for the treatment of IgG4-RD was included in the Priority Review and Approval Procedure by the NMPA. In March 2025, the BLA of this indication was accepted by the NMPA, which is also the second BLA of XINYUE. In August 2025, XINYUE was granted drug registration approval by the NMPA for the treatment of IgG4-RD in adult patients. This is the second indication of XINYUE which has been approved.

In April 2025, Amgen, a collaborator of the Company, announced that inebilizumab for the treatment of IgG4-RD in adult patients had been approved by the FDA, making it the first drug approved by the FDA for the treatment of IgG4-RD.

In May 2025, the third BLA for XINYUE was accepted by the NMPA for the treatment of adult patients with gMG. In March 2026, this indication was granted drug registration approval by the NMPA. This is the third indication of XINYUE which has been approved.

Fulaimei (孚來美®)

Fulaimei (PEG-Loxenatide for Injection) is the first innovative medicine launched leveraging on the Group's proprietary PEGylation technology. It is the first original GLP-1 receptor agonist ("**GLP-1RA**") weekly formulation in China and the world's first PEG GLP-1RA weekly formulation, which was approved in May 2019 for the treatment of type 2 diabetes mellitus. Fulaimei provides a new treatment option that is safe, effective and convenient for type 2 diabetic patients in China, with clear efficacy in lowering blood glucose, combined with weight loss, lowering of cholesterol and blood pressure, renal and cardiovascular benefits, as well as low incidence of gastrointestinal reactions and hypoglycemic adverse events, while requiring only one subcutaneous injection per week. In 2020, Fulaimei was included in the NRDL for the first time and was successfully renewed in November 2024, and is currently within the term of the agreement.

During the Reporting Period, multiple research findings related to Fulaimei were published in internationally renowned journals, including the results of a large-scale multicenter bidirectional cohort real-world study on cardiovascular safety published in *MedComm* (IF:10.7), the results of a real-world study on Fulaimei in combination with insulin therapy published in *Diabetes Therapy*, as well as multiple action mechanism studies on Fulaimei promoting wound healing, improving insulin resistance and lipid metabolism disorders. These results provide new strategies for the clinical treatment of patients with type 2 diabetes and related complications, and support broader clinical application prospects of Fulaimei.

Fulaimei has been included in the *Guidelines for the Prevention and Treatment of Diabetes Mellitus in China (2024 Edition)** (《中國糖尿病防治指南(2024版)》) released by the Chinese Diabetes Society (CDS). It was also included in the *Chinese Expert Consensus on the Comprehensive Management of Patients with Cardiovascular-Kidney-Metabolic Syndrome** (《心血管－腎臟－代謝綜合徵患者的綜合管理中國專家共識》) in March 2025, recommended by the *Expert Consensus on Combination Treatment with a Glucagon-like Peptide-1 Receptor Agonist and Insulin for Treatment of Type 2 Diabetes (2025 Edition)** (《胰高糖素樣肽1受體激動劑聯合胰島素治療 2型糖尿病專家共識(2025 版)》) in April 2025 and included in the *National Guidelines for the Prevention and Control of Diabetes in Primary Care (2025 Edition)** (《國家基層糖尿病防治管理指南(2025)》) in December 2025.

Hengmu (恒沐®)

Hengmu (Tenofovir Amibufenamide Tablets) is a novel nucleotide reverse transcriptase inhibitor (NRTI) self-developed by the Group, which is the first wholly developed oral dose medicine indicated for the treatment of hepatitis B virus infection in China. Hengmu was approved by the NMPA in June 2021 for the treatment of adult patients with chronic hepatitis B. In the same year, Hengmu was included in the NRDL for the first time and was successfully renewed for inclusion in the 2025 NRDL in December 2025.

The 48-week, 96-week and 144-week results of the phase III registration clinical study and the research data of the phase IV study with a follow-up period of up to 5 years (240 weeks) of Hengmu have been published in several academic journals and international conferences. The results of the studies strongly confirmed the efficacy and safety of Hengmu in the long-term treatment of patients with chronic hepatitis B. Specifically, in terms of bone and renal safety, Hengmu has more advantages over tenofovir disoproxil fumarate (TDF).

As of the date of this announcement, findings on multiple clinical studies of Hengmu were presented at top international academic conferences in the field of hepatology, including the American Association for the Study of Liver Diseases (AASLD) Annual Meeting, the European Association for the Study of the Liver (EASL) Annual Meeting and the Asian Pacific Association for the Study of the Liver (APASL) Annual Meeting, and were published in domestic and international journals such as *Alimentary Pharmacology & Therapeutics*, *Frontiers In Pharmacology*, *World Journal of Gastroenterology*, *Journal of Clinical and Translational Hepatology* and *Chinese Journal of Hepatology*.

To date, Hengmu has been recommended by 16 authoritative domestic guidelines and consensuses, including the *Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Edition)** (《慢性乙型肝炎防治指南(2022年版)》), the *Guidelines for the Diagnosis and Treatment of Liver Failure (2024 Edition)** (《肝衰竭診治指南(2024年版)》), the *Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition)** (《原發性肝癌診療指南(2024年版)》), and the *Guidelines for the Prevention and Treatment of Hepatitis B Virus Reactivation in High-Risk Groups in China (2026 Edition)** (《中國高危人群乙型肝炎病毒再激活防治指南(2026年版)》), providing better treatment option for the long-term management of chronic hepatitis B (CHB).

Saint Luolai (聖羅萊®)

Saint Luolai (Pegmolesatide Injection), is the "only class 1 small molecule peptide chemical drug approved worldwide in the field of renal anaemia treatment" self-developed by the Group. In June 2023, Saint Luolai was approved for two indications to treat anemia in chronic kidney disease ("**CKD**") adult patients who have not received ESA and are not on dialysis, as well as those who are receiving short-acting erythropoietin treatment and on dialysis. In 2023, Saint Luolai was included in the NRDL for the first time and was successfully renewed for inclusion in the 2025 NRDL in December 2025.

Saint Luolai has high affinity and selectivity to erythropoietin ("**EPO**") receptor. It effectively promotes erythropoiesis and assists in reducing potential safety risks. The data of the phase III pivotal registrational clinical trial of Saint Luolai (published in *eClinicalMedicine*, a subset of *The Lancet* in 2023) demonstrated that, subcutaneous injection of Saint Luolai once a month is as effective and safe as fast-acting recombinant human erythropoietin (rHuEPO) conventionally administered 1 to 3 times a week in treating anemia in Chinese dialysis patients. It even shows a trend of superiority and a lower incidence of adverse cardiovascular events. Latest post-hoc analyses have demonstrated that the risk of adverse cardiovascular events in the Saint Luolai group was lower than that in the rHuEPO group in both dialysis and non-dialysis patients. A mechanistic study further suggested that the favorable cardiovascular safety profile of Saint Luolai may be attributable to its high selectivity for the EPO receptor. Post-hoc analyses also revealed that, among non-dialysis patients, the Saint Luolai group exhibited higher iron utilization rates and lower iron supplementation requirements compared with the rHuEPO group. Recent studies also found that Saint Luolai's prolonged anti-anemia effect not only results from higher pharmacokinetic half-life due to PEGylation, but is also related to mechanisms such as Pegmolesatide's enhanced EPO receptor binding stability.

As of the date of this announcement, multiple research findings of Saint Luolai have been published in top-tier journals or medical conferences, including *Journal of Translational Medicine*, *Kidney International Reports*, *Kidney Medicine* and *International Immunopharmacology* as well as the American Society of Nephrology (ASN) Annual Meeting and the World Congress of Nephrology (WCN) of the International Society of Nephrology (ISN).

Currently, Saint Luolai has been recommended by a number of guidelines and consensuses, including the *Chinese Expert Consensus on Long-acting Erythropoiesis-stimulating Agents in the Treatment of Renal Anemia (2024 Edition)** (《長效紅細胞生成刺激劑治療腎性貧血中國專家共識(2024年版)》). In particular, in January 2025, Saint Luolai was included in the *Chinese Expert Consensus on Guiding Self-management of Patients with Renal Anemia (2024 Edition)** (《指導腎性貧血患者自我管理的中國專家共識(2024版)》). In July 2025, Saint Luolai was recommended by *Clinical Practice Guideline for Delaying the Progression of Chronic Kidney Disease (2025 Edition)** (《延緩慢性腎臟病進展臨床管理指南(2025年版)》) for therapy and management of renal anemia. In November 2025, Saint Luolai was recommended by the *Chinese Clinical Practice Guidelines for the Management of Peridialysis-Related CKD (2025 Edition)** (《中國圍透析期 CKD 管理臨床實踐指南(2025年版)》) for the treatment of peridialysis-related renal anemia.

R&D and Innovation

Innovation is the core driver of the Company's development. The Group has consistently increased its investment in R&D year by year, established comprehensive R&D platforms, and built a portfolio of proprietary technologies. It has successfully developed and commercialized multiple innovative medicines, while advancing a pipeline of innovative medicines across various stages of development. Our professional R&D team consists of over 2,300 research fellows at 4 R&D centres located in Maryland, United States and Shanghai, Changzhou and Lianyungang, China. We have several national-level R&D designations, including the National Technology Center* (國家級技術中心), Post-doctoral Research Station* (博士後科研工作站) and Key National Laboratory* (國家重點實驗室).

During the year ended December 31, 2025, we submitted 40 formal patent applications in China and 128 formal patent applications overseas, and were granted 80 patents globally.

R&D pipeline update

During the year ended December 31, 2025, the Group had more than 70 clinical trials of innovative medicines being investigated, covering more than 40 innovative medicine candidates.

During the Reporting Period, we had eight new innovative medicine candidates entering clinical stage, including an ADC drug HS-20108 (for advanced solid tumors such as SCLC and neuroendocrine tumors); HS-20122, an ADC targeting EGFR/c-MET (for advanced solid tumors, including NSCLC, head and neck squamous cell carcinoma, or colorectal cancer); HS-10542 (for PNH and IgAN); HS-10510 (for primary hypercholesterolemia and mixed dyslipidemia); HS-10529, a small molecule KRAS G12D inhibitor (for advanced solid tumors with KRAS G12D mutations such as pancreatic cancer, colorectal cancer, NSCLC); HS-20118 (for moderate to severe plaque psoriasis); and cooperative project small molecule BTKi HS-10561 (for chronic spontaneous urticaria).

During the Reporting Period, seven new phase III pivotal registration clinical trials were added, including: HS-20093, a self-developed B7-H3-targeted ADC (for osteosarcoma); HS-20089, a self-developed B7-H4-targeted ADC (for ovarian cancer); HS-20094, a self-developed dual GLP-1/GIP receptor agonist (for diabetes); HS-20137, a monoclonal antibody targeting IL-23p19 in-licensed from Qyuns Therapeutics Co., Ltd. ("**Qyuns**") (for moderate to severe plaque psoriasis); and HS-20117, a bispecific antibody targeting EGFR/c-MET, in-licensed from Biotheus Inc. ("**Biotheus**") (for NSCLC).

R&D progress of late-stage key products

Risvutatug Rezetecan (HS-20093)

Risvutatug Rezetecan, a B7-H3-targeted ADC self-developed by the Group, is composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to topoisomerase inhibitor (TOPOi) payload. In December 2023, the Group entered into an exclusive license agreement with GlaxoSmithKline Intellectual Property (No.4) Limited ("**GSK**"), pursuant to which GSK was granted an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, Macau and Taiwan) to develop, manufacture and commercialize the product.

During the Reporting Period, Risvutatug Rezetecan has entered phase III clinical research for the treatment of osteosarcoma indication in China. Risvutatug Rezetecan has entered phase III clinical research for the treatment of SCLC in China, and is also undergoing multiple proofs of concept (PoC) clinical studies for the treatment of head and neck cancer, castrate-resistant prostate cancer, esophageal squamous cell carcinoma and other solid tumors.

Currently, Risvutatug Rezetecan has obtained a number of regulatory designations, covering various high-clinical-demand solid tumor indications, with details as follows:

Three Breakthrough-Therapy-Designated Drugs were granted by the NMPA of China: in November 2024, for extensive-stage small-cell lung cancer ("**ES-SCLC**") developed after standard first-line treatment (platinum doublet chemotherapy combined with immunotherapy); in February 2025, for the treatment of patients with osteosarcoma who have progressed on at least two prior lines of therapy; in April 2025, for locally advanced or metastatic non-squamous NSCLC without driver mutations, progressed or recurred following platinum-based chemotherapy.

Two BTDs were granted by the U.S. FDA: in August 2024, for the treatment of patients with ES-SCLC with disease progression on or after platinum-based chemotherapy (relapsed or refractory); in January 2025, for the treatment of adult patients with relapsed or refractory osteosarcoma (bone cancer) who have progressed on at least two prior lines of therapy. The FDA granted Orphan Drug Designation ("**ODD**") in December 2025 for the treatment of SCLC.

One Priority Medicines (PRIME) designation was granted by the European EMA in December 2024, for the treatment of patients with relapsed ES-SCLC. One ODD was granted by the EMA in October 2025, for the treatment of pulmonary neuroendocrine cancer, including SCLC.

In October 2025, the results of a phase II study of HS-20093 in the treatment of relapsed or refractory sarcoma were presented orally at the European Society of Medical Oncology ("**ESMO**") Annual Meeting. The results showed that HS-20093 demonstrated promising anti-tumor activity and a manageable safety profile in patients with relapsed or refractory osteosarcoma or other sarcomas.

In December 2025, the results of a phase I study of HS-20093 in patients with NSCLC was presented at the ESMO Asia Meeting. The results showed that HS-20093 demonstrated exciting anti-tumor activity and a manageable safety profile in patients with locally advanced or metastatic NSCLC.

Mocertatug Rezetecan (HS-20089)

Mocertatug Rezetecan is a B7-H4-targeted ADC self-developed by the Group. In October 2023, the Group entered into an exclusive license agreement with GSK, pursuant to which GSK was granted an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, Macau and Taiwan) to develop, manufacture and commercialize the product.

During the Reporting Period, HS-20089 has entered phase III clinical research for the platinum-resistant ovarian cancer ("**PROC**") indication in China and currently is also undergoing PoC clinical studies for the treatment of endometrial cancer and other solid tumors.

In May 2025, HS-20089 was approved by the NMPA as a Breakthrough-Therapy-Designated Drug, with the proposed indication for platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.

In October 2025, the results of the phase II study of HS-20089 for the treatment of patients with PROC who had failed multiple prior lines of therapy were presented at the ESMO Annual Meeting. The study results showed that HS-20089 demonstrated encouraging anti-tumor efficacy and manageable safety profile in patients with PROC who had failed multiple prior lines of therapy.

HS-20094

HS-20094 is a dual GIP and GLP-1 receptor agonist self-developed by the Group. By selectively activating both the GIP and GLP-1 receptors, it promotes insulin secretion, delays gastric emptying, inhibits appetite and reduces food intake, thereby producing biological effects such as glucose control, weight loss and metabolic improvement. Its administration method is once a week via subcutaneous injection. The relevant clinical studies have administered the drug to over a thousand subjects. During the Reporting Period, the indication of HS-20094 for the treatment of type 2 diabetes mellitus has entered into phase III clinical research stage in China. Currently, a phase III clinical study of HS-20094 in the treatment of obesity or overweight is ongoing.

HS-10374

HS-10374 is a selective allosteric inhibitor of tyrosine kinase 2 ("**TYK2**") self-developed by the Group. In phase II clinical trial in patients with moderate-to-severe plaque psoriasis, HS-10374 demonstrated significant efficacy, with overall safety similar to other TYK2 inhibitors and a lower risk of skin-related toxicity. Currently, we are actively advancing phase III clinical studies of HS-10374 in adult patients with moderate-to-severe plaque psoriasis.

HS-10365

HS-10365 capsules is a potent and selective RET inhibitor self-developed by the Group. In October 2025, its NDA has been accepted by the NMPA for the treatment of adult patients with RET fusion-positive locally advanced or metastatic NSCLC.

Dalmelitinib Mesylate Tablets (HS-10241)

Dalmelitinib Mesylate Tablets is an orally administered, highly selective c-MET TKI self-developed by the Group, for the treatment of patients with locally advanced or metastatic EGFR mutation-positive NSCLC whose tumors have mesenchymal to epithelial transition factor ("**MET**") amplification after prior EGFR TKI therapy. As of the date of this announcement, the NDA for Dalmelitinib Mesylate Tablets in combination with Aumolertinib Mesylate Tablets (Ameile 阿美樂®) has been accepted by the NMPA.

Business Development

As an important part of our daily business, the Group pays close attention to the cutting-edge developments in the global pharmaceutical industry and proactively seizes opportunities for out-licensing and collaboration in Business Development ("**BD**"). On December 18, 2024, the Group entered into a license agreement with a wholly-owned subsidiary of Merck Sharp & Dohme LLC ("**MSD**"), pursuant to which, the Group received an upfront payment of US$112 million of BD license fee from collaborator MSD during the Reporting Period, which was included in collaboration revenue. In addition, (i) on June 2, 2025, the Group granted an exclusive license to Regeneron for its investigational dual GLP-1/GIP receptor agonist HS-20094; (ii) on October 16, 2025, the Group granted an exclusive license to Roche for a novel CDH17-targeting ADC HS-20110; and (iii) on December 16, 2025, the Group granted an exclusive license to Glenmark for Aumolertinib in multiple territories. See below for details.

Collaboration with Regeneron

On June 2, 2025, Shanghai Hansoh Biomedical Co., Ltd.* (上海翰森生物醫藥科技有限公司) and Jiangsu Hansoh Pharmaceutical Group Co., Ltd.* (江蘇豪森藥業集團有限公司) ("**Jiangsu Hansoh**"), wholly-owned subsidiaries of the Company, entered into a license agreement with Regeneron. Pursuant to the license agreement, the Group granted an exclusive worldwide license (excluding Chinese Mainland, Hong Kong and Macau) to Regeneron to develop, manufacture, and commercialize HS-20094. The transaction amount of the agreement is up to US$2.01 billion, comprising an upfront payment and milestone payments, plus tiered royalties on potential future product sales.

Collaboration with Roche

On October 16, 2025, Shanghai Hansoh Biomedical Co., Ltd.* (上海翰森生物醫藥科技有限公司) and Changzhou Hansoh Pharmaceutical Co., Ltd.* (常州恒邦藥業有限公司), wholly-owned subsidiaries of the Company, entered into a license agreement with Roche. Pursuant to the license agreement, the Group granted an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, Macau and Taiwan) to Roche to develop, manufacture and commercialize HS-20110. The transaction amount of the agreement is up to US$1.53 billion, comprising an upfront payment and milestone payments, plus tiered royalties on potential future product sales.

Collaboration with Glenmark

On December 16, 2025, Jiangsu Hansoh, a wholly-owned subsidiary of the Company, entered into an exclusive license, collaboration and distribution agreement with Glenmark. Pursuant to the license agreement, the Group granted an exclusive license to Glenmark to develop and commercialize Aumolertinib across its licensed territories: the Middle East and Africa, Southeast and South Asia, Australia, New Zealand, Russia/CIS and a few selected Caribbean countries covered by the license agreement. Pursuant to the agreement, Glenmark is required to pay upfront payment. The transaction amount of the agreement could exceed US$1 billion, comprising an upfront payment and milestone payments, plus tiered royalties on potential future product sales.

Clinical Progress of In-licensing and Collaboration Programs

During the Reporting Period, the Group incurred a total of approximately RMB332 million of R&D expenses due to the in-licensed or collaborative projects that had been introduced in the past, which were mainly used to advance the clinical trials of a number of in-licensed projects.

Progress of HS-20122

In March 2024, the Group entered into a licensing agreement with Biotheus and obtained an exclusive license from Biotheus to use bispecific antibodies targeting EGFR/c-MET, including HS-20117, for the development, production and commercialization of antibody conjugate products globally, with the right to further sub-license.

HS-20122 is a bispecific ADC developed based on HS-20117 that targets EGFR/c-MET. In April 2025, HS-20122 obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for advanced solid tumors, including NSCLC, head and neck squamous cell carcinoma, or colorectal cancer.

Progress on HS-20137

In April 2024, the Group entered into a licensing agreement with Qyuns and obtained an exclusive license from Qyuns to develop and commercialize HS-20137 in China (including Hong Kong, Macau and Taiwan) (collaborator code QX004N).

In March 2025, the findings of phase II clinical trial of HS-20137 for plaque psoriasis in adults were presented at the American Academy of Dermatology (AAD) Annual Meeting. The trial results show that during the 28-week treatment period, HS-20137 shows strong efficacy and favorable safety profile in patients with moderate to severe plaque psoriasis. The results were consistent with the phase I study results published in *JAMA Dermatology*.

HS-20137 is a monoclonal antibody that targets IL-23p19. During the Reporting Period, HS-20137 for the treatment of adult patients with moderate to severe plaque psoriasis entered into phase III clinical study in China.

Progress on HS-10561

In August 2024, the Group entered into a licensing agreement with Lupeng Pharma and obtained an exclusive license from Lupeng Pharma to develop and commercialize HS-10561 (collaborator code LP-168) in China (including Hong Kong, Macau and Taiwan). The Group is responsible for the R&D, regulatory approval, manufacturing and commercialization of this product in all non-oncology indications in China.

HS-10561 is a small molecule BTKi. In February 2025, HS-10561 capsules obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for chronic spontaneous urticaria. During the Reporting Period, HS-10561 for the treatment of patients with chronic spontaneous urticaria entered into phase I/II clinical studies in China.

Progress on HS-10518

In August 2022, the Group entered into an exclusive license agreement with TiumBio Co., Ltd., pursuant to which the Group was granted an exclusive license to develop and commercialize HS-10518 (collaborator code TU2670) in the PRC, including Hong Kong, Macau and Taiwan, for gynecology-related indications.

HS-10518 is an orally active non-peptide GnRH antagonist. According to the completed early clinical studies, its safety and tolerability were favorable. As of the end of the Reporting Period, HS-10518 for assisted reproductive technology (ART) treatment was in phase II clinical study in China.

Progress on HS-10568

In December 2025, the Group and Hengrui entered into a licensing agreement. Pursuant to the agreement, the Group obtained an exclusive license from Hengrui to develop, manufacture and commercialize HS-10568 (collaborator code SHR6508) in the PRC (excluding Hong Kong, Macau and Taiwan), with the right of sublicense in accordance with the relevant terms of the license agreement.

HS-10568 is an allosteric modulator of calcium-sensing receptor (CaSR) which increases the receptor's sensitivity to extracellular calcium, thereby inhibiting the secretion of parathyroid hormone (PTH). As of the end of the Reporting Period, HS-10568 for the treatment of secondary hyperparathyroidism in adult patients with CKD requiring hemodialysis was in phase III clinical study.

Environmental, Social and Governance (ESG)

Adhering to our core values of "responsibility, integrity, hard work and innovation", the Group has in the long term been committed to improving the accessibility of innovative medicines in the areas of unfulfilled clinical needs. During the Reporting Period, we continued to optimize in terms of R&D innovation, governance, environmental protection, talent cultivation and inclusive healthcare, laying a solid foundation for the long-term development of the Company. We are continuously improving the disclosures of our governance, strategy, risk management, metrics and targets on key ESG issues in response to stakeholders' concerns, as well as enhancing the level of ESG management to lower operating risks.

In 2025, the Board continued to perform its supervisory duties and, through the ESG Committee, regularly reviewed risk prevention strategies and systems, ESG strategies and emerging risks, as well as key performance indicators that reflect the comprehensive improvement of ESG results, and responded to identified hidden hazards or potential risks with forward-looking actions. During the Reporting Period, we engaged a third party to provide independent assurance on our 2024 ESG report, and continued to conduct systematic inspections and third-party verification of Scope 1, Scope 2 and Scope 3 greenhouse gases, to ensure accuracy, completeness and reliability of information and data for ESG disclosure.

As of the date of this announcement, the MSCI ESG rating of the Group was upgraded to the highest level of AAA and the Group achieved global industry leading standards in all key issues including corporate governance, toxic emissions and waste, product safety and quality, human resource development as well as inclusive healthcare. The Group was again selected for inclusion in the *Sustainability Yearbook (Global Edition) 2026* and the *Sustainability Yearbook (China Edition) 2025* published by S&P, and ranked among the top 1% in the Chinese pharmaceutical industry. The Group achieved a score of 74 in S&P's 2025 Corporate Sustainability Assessment (CSA), retaining the top spot in China's pharmaceutical industry again. At the same time, in the 2025 corporate environmental information disclosure rating of the Carbon Disclosure Project (CDP), the Group received a B rating for climate change and a B rating for water safety, maintaining a leading position among the top pharmaceutical enterprises in the PRC. Jiangsu Hansoh, the Group's main entity for production and operations, has continuously improved its sustainable supply chain and received the EcoVadis Bronze Medal. In addition, we have also won awards such as the ESG New Benchmark Enterprise Award awarded by Securities Star and Forbes China Best Employer Award.

We actively respond to the Sustainable Development Goals of the United Nations, deeply integrating ESG management into the Company's long-term planning, and proactively addressing challenges in the ESG domains to contribute to global sustainability. We are committed to sharing proven practices with partners across the industry value chain, striving to enable green innovations to benefit a broader medical community and bring new hope to areas of unmet clinical needs. This is not only conducive to natural environment protection and social welfare, but also beneficial to creating a more stable and sustainable business environment, realizing coordinated economic, social and environmental development. Going forward, we will continue to adhere to the philosophy of being "patient-centered and innovation-driven", actively fulfilling our responsibilities as a corporate citizen and creating long-term value for the industry and society.

FINANCIAL REVIEW

Revenue

During the Reporting Period, the Group's revenue amounted to approximately RMB15,028 million, representing an increase of approximately 22.6% as compared to approximately RMB12,261 million for the year ended December 31, 2024. The Group's revenue primarily generates from the sales of pharmaceutical products, major products are concentrated in the main therapeutic areas on which the Group strategically focuses, including oncology, anti-infectives, CNS, metabolic and other diseases. The increase in revenue during the Reporting Period was primarily due to the increase in the revenue of innovative medicines and collaborative products.

Cost of Sales

The Group's cost of sales increased by approximately 35.5% from approximately RMB1,105 million for the year ended December 31, 2024 to approximately RMB1,498 million for the Reporting Period, which accounted for approximately 10.0% of the Group's total revenue for the same year. The increase in cost of sales of the Group was mainly attributable to the increased sales of products for the Reporting Period, as compared to the year ended December 31, 2024.

Other Income

The Group's other income mainly consisted of government grants, interest income and other income. During the Reporting Period, the Group's other income amounted to approximately RMB1,209 million, representing an increase of approximately 6.7% as compared to approximately RMB1,133 million for the year ended December 31, 2024. The increase was mainly attributable to increased interest income during the year.

Selling and Distribution Expenses

The Group's selling and distribution expenses consisted of expenses that were directly related to the Group's marketing and promotion activities. During the Reporting Period, the Group's selling and distribution expenses amounted to approximately RMB4,064 million, representing an increase of approximately 7.1% as compared to approximately RMB3,796 million for the year ended December 31, 2024. The increase was mainly attributable to the growth of sales revenue.

Administrative Expenses

The Group's administrative expenses primarily consisted of staff costs, general operating expenses, depreciation and amortization, auditor's remuneration, consulting expenses, taxation and other administrative expenses. During the Reporting Period, the Group's administrative expenses amounted to approximately RMB672 million, representing a decrease of approximately 5.7% as compared to approximately RMB713 million for the year ended December 31, 2024. The decrease was mainly due to strengthened cost controls during the year.

R&D Expenses

The Group's R&D expenses primarily consisted of employee costs, CRO and experiment costs, material expenses, energy expenses, BD expenses, depreciation and amortization and other R&D expenses. During the Reporting Period, the Group's R&D expenses amounted to approximately RMB3,358 million, representing an increase of approximately 24.3% as compared to approximately RMB2,702 million for the year ended December 31, 2024. The increase was primarily attributable to the fact that the Group has focused on innovation and consistently increased its investment in R&D year by year, established comprehensive R&D platforms, developing and launching multiple innovative medicine products and reserving pipelines of innovative medicines at various stages of development.

Other (Expenses)/Gains, Net

The Group's other (expenses)/gains, net primarily consisted of fair value (losses)/gains of financial assets at fair value through profit or loss, donations, foreign exchange differences, net and impairment of inventories, net, etc. For the Reporting Period, the Group's other expenses amounted to approximately RMB92 million, as compared to other gains of approximately RMB13 million for the year ended December 31, 2024. The change was mainly due to increased fair value losses of financial assets at fair value through profit or loss and foreign exchange losses during the year.

Finance Costs

During the Reporting Period, the Group's finance costs amounted to approximately RMB3 million, representing a decrease of approximately 52.7% as compared to approximately RMB7 million for the year ended December 31, 2024. The decrease was mainly due to the decreased bank interest costs for the Reporting Period, as compared to the year ended December 31, 2024.

Income Tax Expense

During the Reporting Period, the Group's income tax expense amounted to approximately RMB995 million, representing an increase of approximately 39.5% as compared to approximately RMB713 million for the year ended December 31, 2024. The increase in the Group's income tax expense was primarily attributable to the increase in profit before tax for the Reporting Period as compared to the year ended December 31, 2024.

Profit for the Year

The Group's profit for the Reporting Period was approximately RMB5,555 million, representing an increase of approximately 27.1% as compared to approximately RMB4,372 million for the year ended December 31, 2024, which was primarily due to the increase in revenue of innovative medicines and collaborative products.

Liquidity and Financial Resources

Currently, the Group follows a set of funding and treasury policies to manage its capital resources and mitigate potential risks. The Board considers various funding sources depending on the Group's funding needs to ensure that the financial resources have been used in the most cost-effective and efficient way. We also closely monitor uses of cash resources and strive to maintain healthy liquidity for the needs of our business operations.

For the year ended December 31, 2025, the Group's operating activities generated a net cash inflow of RMB6,738 million. The capital expenditure during the Reporting Period was RMB458 million, mainly relating to the construction of workshops, as well as, among other things, the purchase of equipment, motor vehicles and software required for production, R&D and administrative activities, etc. The cash flow of financing activities for the Reporting Period mainly consisted of proceeds from the placement of new shares, which was approximately RMB3,558 million.

The Group's financial position remains sound. As at December 31, 2025, the Group had net current assets of approximately RMB31,160 million, as compared to approximately RMB24,747 million as at December 31, 2024. The increase in net current assets was mainly attributable to increased cash and bank balances. The current ratio of the Group decreased to approximately 8.1 as at December 31, 2025 from approximately 10.2 as at December 31, 2024, primarily due to the increased contract liabilities in the year. As at December 31, 2025, we had cash and bank balances of RMB31,549 million (as at December 31, 2024: RMB22,622 million) and current financial assets at fair value through profit or loss of RMB18 million (as at December 31, 2024: RMB17 million). As at December 31, 2025, our current financial assets at fair value through profit or loss primarily comprised financial products issued by commercial banks. As each of the financial products was subscribed with different banks under different terms and are of different nature and none of the financial products exceeds 5% of the applicable percentage ratios on a standalone basis, the Group's purchase of financial products during the year ended December 31, 2025 does not constitute notifiable transactions of the Company under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). As at December 31, 2025, the Group's gearing ratio (calculated as total liabilities divided by total assets) was approximately 11.4% (as at December 31, 2024: 9.4%). The increase in gearing ratio was primarily due to the increased current liabilities in the year. After reviewing the Group's profitability, working capital and capital expenditure requirements, the Board is of the view that the Group has no significant liquidity risk and has sufficient working capital.

Most of the Group's assets and liabilities are denominated in Renminbi and United States Dollars. The Group manages its foreign exchange risk by closely monitoring its net foreign exchange exposure to reduce the impact of foreign exchange fluctuations.

Pledge of Group Assets

As at December 31, 2025, none of the Group's assets was subject to any encumbrance, mortgage, lien, charge or pledge.

Contingent Liabilities

As at December 31, 2025, the Group had no material contingent liabilities.

Significant Investments Held

During the Reporting Period, the Group did not have any significant investments.

Future Plans for Material Investments and Capital Assets

As at December 31, 2025, the Group did not have any plans for material investments and capital assets.

Material Acquisitions and Disposals

During the Reporting Period, the Group did not have any material acquisitions or disposals of subsidiaries, associates or joint ventures.

Employees and Emoluments Policy

As at December 31, 2025, the Group had a total of 9,347 full-time employees, whose remuneration was determined based on their performance and experience as well as the prevailing market salary levels.

The staff costs, including remuneration of the executive Directors, social welfare and other benefits, were approximately RMB3,422 million for the year ended December 31, 2025. We also provided regular training to employees designed to strengthen staff commitment to us and improve staff knowledge in a number of important areas of our services, such as knowledge about the Company and our products as well as sales, laws and regulations applicable to our operation, requirements under applicable GMP or other certifications, quality control, production safety and corporate culture.

The Company has conditionally approved and adopted the restricted share unit scheme ("**RSU Scheme**") on May 27, 2019 to recognize contributions by selected participants and give incentives thereto in order to retain them for the continual operation and development of the Group and to attract suitable personnel for further development of the Group. Participants may include employees of the Group (including director, chief executive officer, vice president, financial controller, company secretary, members of senior management or key technical personnel) as well as any other person selected by the Board at its sole discretion from time to time (subject to compliance with the applicable Listing Rules).

On April 22, 2025, pursuant to the terms of the RSU Scheme, the Company allotted and issued 11,500,000 new ordinary shares (aggregate nominal value: HK$115) to Computershare Hong Kong Trustees Limited (the "**RSU Trustee**"), holding such shares for the benefit of the participants of the RSU Scheme, with the issue price per share of HK$2.9595 as measured by the Company, which was arrived at after taking into consideration the number of shares currently held by the RSU Trustee and the purchase prices of the RSUs at the time of measurement, and the closing price per share of the Company on the business day immediately preceding the issuance is HK$22.10. During the Reporting Period, the RSU Trustee was not instructed by the Company to purchase any shares from the open market. As at December 31, 2025, a balance of 1,194,647 shares of the Company was held by the RSU Trustee for settlement of the restricted share units ("**RSUs**") under the RSU Scheme. For details of the RSU Scheme, please refer to the section headed "Statutory and General Information – D. Post-IPO RSU Scheme" in Appendix IV to the prospectus of the Company dated May 31, 2019.

During the Reporting Period, RSUs representing an aggregate of 8,560,990 shares of the Company had been granted by the Company pursuant to the RSU Scheme. Among the grants during the Reporting Period (details of the grants are set out in the announcement of the Company dated April 28, 2025), all RSUs granted to Dr. Lyu Aifeng (representing 211,910 shares of the Company granted), being an executive Director of the Company, only involve existing shares of the Company held or to be held by the RSU Trustee, and no new shares were or will be allotted or issued by the Company for the vesting of such RSUs. According to the director's service contract with the Company, the RSUs granted to him form part of his remuneration package and are therefore exempted from the reporting, announcement and independent shareholders' approval requirements under Rules 14A.73(6) and 14A.95 of the Listing Rules.

Prospects

The Group operates an innovation-driven business model that integrates in-house R&D, global strategic collaborations and the commercialization of innovative medicines. Over the past several years, the Group has continued to increase investment in R&D and has gradually built a diversified innovation pipeline spanning multiple therapeutic areas. This, along with the Group's established commercialization infrastructure in China and its expanding global development capabilities, provides an important foundation for the Group's long-term development.

As innovative medicine candidates continue to advance through clinical development and regulatory approvals, the Group's pipeline is expected to provide opportunities for future commercialization in the Chinese market. At the same time, certain innovation programs may also generate opportunities for global licensing and collaboration, enabling the Group to explore the ex-China commercialization potential of its pipeline. Through ongoing collaboration with external partners, the Group continues to strengthen its global development capabilities while seeking to unlock the broader value of its innovation programs.

Industry activity in licensing and collaboration transactions has remained robust in recent years, particularly for innovative assets originating from the PRC. According to industry statistics, the global pharmaceutical industry recorded more than 1,000 licensing and collaboration transactions in 2025, with total disclosed transaction amount of approximately US$275 billion, representing year-on-year growth of around 30%. China-related pharmaceutical transactions also increased significantly, with over 300 transactions reported in 2025, and the associated transaction amount accounting for close to half of global transaction amount. These trends reflect the increasing recognition by international markets of PRC-origin innovative pharmaceutical assets and the growing global focus in differentiated innovation pipelines.

Against this industry backdrop, the Group has continued to increase the contribution of innovative medicines and collaboration income to its overall revenue structure. Currently, approximately 80% of the Group's revenue is derived from innovative medicines and collaboration products as well as collaboration revenue. As the innovation pipeline matures and more products advance toward commercialization, the Group expects innovative medicines to remain an important driver of its future growth.

A number of the Group's marketed innovative medicines currently remain in the commercialization expansion phase. As clinician awareness of these medicines continues to improve and market penetration continues to increase, these products are expected to contribute a higher proportion of the Group's revenue. In particular, the inclusion of multiple innovative medicines in the NRDL has effectively improved patient accessibility and affordability, providing strong support for the broader adoption of these therapies in the PRC market.

At the same time, the pharmaceutical industry remains highly competitive and subject to ongoing technological change. Policy and regulatory frameworks in the PRC healthcare sector also continue to be refined, including potential adjustments in areas such as drug approval, pricing and reimbursement mechanisms under medical insurance. In addition, the R&D of innovative medicines is characterized by significant investment requirements and high inherent uncertainty, and drug candidates may ultimately fail to obtain regulatory approval, achieve successful commercialization or attain expected levels of market acceptance.

Looking ahead, the Group will continue to develop pipelines in core disease areas including oncology, CNS, metabolism and immunology, and will continue to seek global strategic collaborations at appropriate juncture, with a view to further expanding the international development and commercialization potential of its innovation assets. As an innovation-driven pharmaceutical company, we continue to bring innovative treatment options to patients with significant unmet medical needs.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

	Notes	For the year ended December 31, 2025 RMB'000 (Audited)	2024 RMB'000 (Audited)
REVENUE	*5*	**15,028,324**	12,260,814
Cost of sales		**(1,497,867)**	(1,105,408)
Gross profit		**13,530,457**	11,155,406
Other income	*5*	**1,208,919**	1,133,336
Selling and distribution expenses		**(4,063,790)**	(3,795,848)
Administrative expenses		**(671,716)**	(712,546)
Research and development costs		**(3,357,981)**	(2,701,650)
Other (expenses)/gains, net	*5*	**(92,146)**	13,173
Finance costs		**(3,162)**	(6,689)
PROFIT BEFORE TAX	*6*	**6,550,581**	5,085,182
Income tax expense	*7*	**(995,120)**	(713,357)
PROFIT FOR THE YEAR		**5,555,461**	4,371,825
Attributable to owners of the parent		**5,555,461**	4,371,825
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	*9*		
Basic (RMB)		**0.93**	0.74
Diluted (RMB)		**0.93**	0.73

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Notes	For the year ended December 31, 2025 **RMB'000** **(Audited)**	2024 *RMB'000* (Audited)
PROFIT FOR THE YEAR		**5,555,461**	4,371,825
OTHER COMPREHENSIVE (LOSS)/INCOME			
Other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods:			
Exchange differences on translation of foreign operations		**(583,679)**	234,447
Net other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods		**(583,679)**	234,447
OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE YEAR, NET OF TAX		**(583,679)**	234,447
TOTAL COMPREHENSIVE INCOME FOR THE YEAR		**4,971,782**	4,606,272
Attributable to owners of the parent		**4,971,782**	4,606,272

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	Notes	As at December 31, 2025 RMB'000 (Audited)	2024 RMB'000 (Audited)
NON-CURRENT ASSETS			
Property, plant and equipment		**2,758,000**	2,804,765
Right-of-use assets		**421,344**	442,405
Intangible assets		**362,647**	245,286
Financial assets at fair value through profit or loss		**772,486**	702,283
Prepayments for purchase of property, plant and equipment		**30,532**	21,315
Total non-current assets		**4,345,009**	4,216,054
CURRENT ASSETS			
Inventories		**608,922**	651,224
Trade and bills receivables	*10*	**3,060,517**	3,169,763
Prepayments, other receivables and other assets		**319,623**	234,537
Financial assets at fair value through profit or loss		**17,612**	17,237
Other financial assets		**–**	747,468
Cash and bank balances	*11*	**31,548,668**	22,621,566
Total current assets		**35,555,342**	27,441,795
CURRENT LIABILITIES			
Trade payables	*12*	**334,314**	217,851
Other payables and accruals	*13*	**2,562,579**	2,354,591
Contract liabilities		**1,181,478**	19,227
Convertible bonds		**40,501**	40,874
Lease liabilities		**16,968**	16,006
Tax payable		**259,094**	46,669
Total current liabilities		**4,394,934**	2,695,218
NET CURRENT ASSETS		**31,160,408**	24,746,577
TOTAL ASSETS LESS CURRENT LIABILITIES		**35,505,417**	28,962,631

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONTINUED)

	Notes	As at December 31, 2025 ***RMB'000*** **(Audited)**	2024 *RMB'000* (Audited)
NON-CURRENT LIABILITIES			
Lease liabilities		**47,624**	61,013
Deferred tax liabilities		**72,299**	200,189
Other non-current liabilities		**21,043**	21,515
Total non-current liabilities		**140,966**	282,717
NET ASSETS		**35,364,451**	28,679,914
EQUITY			
Equity attributable to owners of the parent			
Share capital	*14*	**53**	52
Treasury shares		**(2,885)**	(13,215)
Reserves		**35,367,283**	28,693,077
Total equity		**35,364,451**	28,679,914

1. CORPORATE AND GROUP INFORMATION

The Company is an exempted company incorporated in the Cayman Islands with limited liability under the Companies Law of the Cayman Islands. The registered address of the Company is the offices of Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.

The shares of the Company were listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on 14 June 2019.

The Company is an investment holding company. The Company and its subsidiaries (together, the "**Group**") were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China (the "**PRC**").

2. BASIS OF PREPARATION

These financial statements have been prepared in accordance with HKFRS Accounting Standards (which include all Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards ("**HKASs**") and Interpretations) as issued by the Hong Kong Institute of Certified Public Accountants ("**HKICPA**") and the disclosure requirements of the Hong Kong Companies Ordinance. They have been prepared under the historical cost convention, except for financial assets at fair value through profit or loss, bills receivable, and derivatives embedded in the convertible bonds which have been measured at fair value. These financial statements are presented in Renminbi ("**RMB**") and all values are rounded to the nearest thousand except when otherwise indicated.

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The Group has adopted amendments to HKAS 21 *Lack of Exchangeability* for the first time for the current year's financial statements. The Group has not early adopted any other standard or amendment that has been issued but is not yet effective.

Amendments to HKAS 21 specify how an entity shall assess whether a currency is exchangeable into another currency and how it shall estimate a spot exchange rate at a measurement date when exchangeability is lacking. The amendments require disclosures of information that enable users of financial statements to understand the impact of a currency not being exchangeable. As the currencies that the Group had transacted in and the functional currencies of overseas subsidiaries, joint ventures and associates for translation into the Group's presentation currency were exchangeable, the amendments did not have any impact on the Group's financial statements.

In addition, the HKICPA has issued amendments to Illustrative Examples on HKFRS 7, HKFRS 18, HKAS 1, HKAS 8, HKAS 36 and HKAS 37 *Disclosures about Uncertainties in the Financial Statements*, which added illustrative examples in the corresponding HKFRS Accounting Standards. These examples reflect existing requirements in the corresponding HKFRS Accounting Standards to report the effects of uncertainties in the financial statements using climate-related examples. Therefore, the amendments do not have an effective date or transitional provisions. The Group has considered the guidance in these illustrative examples and the amendments did not have any impact on the Group's financial statements.

4. OPERATING SEGMENT INFORMATION

Information about geographical areas

Since about 80% of the Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland and most of the Group's identifiable operating assets and liabilities were located in Chinese mainland, no geographical segment information in accordance with HKFRS 8 *Operating Segments* is presented.

Information about major customers

No revenue from the Group's sales to a single customer amounted to 10% or more of the Group's revenue during the Reporting Period.

5. REVENUE, OTHER INCOME AND OTHER (EXPENSES)/GAINS, NET

An analysis of revenue, other income and other (expenses)/gains, net is as follows:

	2025	2024
	RMB'000	*RMB'000*
Revenue from contracts with customers		
Pharmaceutical products related sales – at a point in time	**12,912,719**	10,687,946
Collaboration revenue – at a point in time	**2,115,605**	1,572,868
Total	**15,028,324**	12,260,814
Other income		
Investment income	**17,012**	50,723
Government grants	**110,040**	85,754
Bank interest income	**1,080,825**	995,259
Others	**1,042**	1,600
Total other income	**1,208,919**	1,133,336
Other (expenses)/gains, net		
Gain on disposal of items of property, plant and equipment	**4,301**	5,721
Loss on derecognition of financial assets at amortised cost	**(4,358)**	(17,143)
Fair value (losses)/gains of financial assets at fair value through profit or loss	**(12,354)**	78,410
Donations	**(9,109)**	(35,438)
Foreign exchange differences, net	**(44,064)**	21,428
Impairment of trade receivables, net	**831**	18,179
Impairment of inventories, net	**(21,376)**	(11,289)
Impairment of property, plant and equipment	**–**	(31,976)
Others	**(6,017)**	(14,719)
Total other (expenses)/gains, net	**(92,146)**	13,173

6. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

	Note	**2025**	2024
		RMB'000	*RMB'000*
Cost of inventories sold		**1,126,049**	874,217
Depreciation of property, plant and equipment		**351,012**	362,335
Depreciation of right-of-use assets		**28,660**	25,777
Amortisation of intangible assets		**13,346**	13,237
Impairment of trade receivables, net	*10*	**(831)**	(18,179)
Impairment of inventories, net		**21,376**	11,289
Impairment of property, plant and equipment		**–**	(31,976)
Operating lease expenses		**4,677**	4,507
Auditors' remuneration:			
Audit services		**3,250**	3,230
Non-audit services		**80**	100
Gain on disposal of items of property, plant and equipment		**(4,301)**	(5,721)
Investment income		**(17,012)**	(50,723)
Fair value losses/(gains) of financial assets at fair value through profit or loss		**12,354**	(78,410)
Bank interest income		**(1,080,825)**	(995,259)
Foreign exchange differences, net		**44,064**	(21,428)
Employee benefit expense (including directors' remuneration):			
Wages and salaries		**2,268,906**	2,183,878
Social welfare and other benefits*		**1,009,501**	1,006,062
Share-based payments		**143,268**	137,725
Total		**3,421,675**	3,327,665

* There are no forfeited contributions that may be used by the Group as the employer to reduce the existing level of contributions.

7. INCOME TAX

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Pursuant to the rules and regulations of the Cayman Islands and the British Virgin Islands, the Group is not subject to any income tax in the Cayman Islands or the British Virgin Islands.

Hong Kong profits tax has been provided at the rate of 16.5% (2024: 16.5%) on the estimated assessable profits arising in Hong Kong during the Reporting Period, except for one subsidiary of the Group which is a qualifying entity under the two-tiered profits tax rates regime. The first HK$2,000,000 (2024: HK$2,000,000) of assessable profits of each subsidiary are taxed at 8.25% (2024: 8.25%) and the remaining assessable profits are taxed at 16.5% (2024: 16.5%).

The provision for PRC corporate income tax is based on the statutory rate of 25% of the assessable profits of certain PRC subsidiaries of the Group as determined in accordance with the PRC Corporate Income Tax Law which was approved and became effective on 1 January 2008, except for certain subsidiaries of the Group in Chinese mainland which are granted tax concession and are taxed at preferential tax rates.

In 2023, Jiangsu Hansoh Pharmaceutical Group Co., Ltd. and Shanghai Hansoh Biomedical Co., Ltd., subsidiaries of the Company, renewed their high and new technology enterprise ("**HNTE**") qualification and were entitled to a preferential income tax rate of 15% for a period of three years from 2023 to 2025.

In 2024, Changzhou Hansoh Pharmaceutical Co., Ltd., a subsidiary of the Company, renewed its HNTE qualification and was entitled to a preferential income tax rate of 15% for a period of three years from 2024 to 2026.

The income tax expense of the Group for the year is analysed as follows:

	2025	2024
	RMB'000	*RMB'000*
Current income tax	**1,123,010**	768,188
Deferred income tax	**(127,890)**	(54,831)
Total	**995,120**	713,357

8. DIVIDENDS

	2025	2024
	RMB'000	*RMB'000*
2024 Final dividends declared – HK$13.53 cents (2023 Final dividends declared – HK$14.22 cents) per ordinary share	**734,910**	768,760
2025 Interim dividends declared – HK$23.16 cents (2024 Interim dividends declared – HK$20.10 cents) per ordinary share	**1,277,674**	1,089,973

Pursuant to the resolution of the shareholders of the Company dated 20 June 2025 and the resolution of the board of directors dated 18 August 2025, the Company declared dividends of HK$13.53 cents (2024: HK$14.22 cents) and HK$23.16 cents (2024: HK$20.10 cents) separately per ordinary share, amounting to a total of approximately RMB2,012,584,000 (2024: RMB1,858,733,000).

9. EARNINGS PER SHARE

The calculation of basic earnings per share is based on the profit for the year attributable to ordinary equity holders of the parent of RMB5,555,461,000 (2024: RMB4,371,825,000), and the weighted average number of ordinary shares of 5,962,903,160 (2024: 5,930,095,672) outstanding during the year, which are adjusted to reflect the changes in the number of ordinary shares during the year.

The calculation of the diluted earnings per share amounts is based on the profit for the year attributable to ordinary equity holders of the parent, adjusted to reflect the interest on the convertible bonds. The weighted average number of ordinary shares used in the calculation of the diluted earnings per share is the weighted average number of ordinary shares outstanding during the year, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares assumed to have been issued on the conversion of all dilutive potential shares into ordinary shares.

The calculations of basic and diluted earnings per share are based on:

	2025	2024
	RMB'000	*RMB'000*
Earnings		
Profit attributable to ordinary equity holders of the parent used in the basic earnings per share calculation	**5,555,461**	4,371,825
Interest on convertible bonds	**541**	535
Profit attributable to ordinary equity holders of the parent used in the diluted earnings per share calculation	**5,556,002**	4,372,360

	Adjusted number of shares	
	2025	2024
Shares		
Weighted average number of ordinary shares outstanding during the year used in the basic earnings per share calculation	**5,962,903,160**	5,930,095,672
Effect of dilution – weighted average number of ordinary shares:		
Restricted share units	**17,068,089**	19,180,723
Convertible bonds	**725,912**	712,371
Weighted average number of ordinary shares outstanding during the year used in the diluted earnings per share calculation	**5,980,697,161**	5,949,988,766
Basic earnings per share (RMB per share)	**0.93**	0.74
Diluted earnings per share (RMB per share)	**0.93**	0.73

10. TRADE AND BILLS RECEIVABLES

	2025	2024
	RMB'000	*RMB'000*
Trade receivables	**3,050,099**	3,139,904
Impairment	**(11,594)**	(12,425)
Net carrying amount	**3,038,505**	3,127,479
Bills receivable	**22,012**	42,284
Total	**3,060,517**	3,169,763

The Group's trading terms with its customers are mainly on credit, except for new customers, whose payment in advance is normally required. The credit period is generally from 60 to 180 days. The Group seeks to maintain strict control over its outstanding receivables and has a credit control department to minimise credit risk. Overdue balances are reviewed regularly by senior management. In view of the aforementioned and the fact that the Group's trade receivables relate to a large number of diversified customers, there is no significant concentration of credit risk. The Group does not hold any collateral or other credit enhancements over its trade and bills receivable balances. Trade and bills receivables are non-interest-bearing.

An ageing analysis of trade receivables as at the end of the Reporting Period, based on the invoice date and net of loss allowance, is as follows:

	2025	2024
	RMB'000	*RMB'000*
Within 90 days	**3,023,697**	3,105,364
91 days to 180 days	**13,024**	5,447
Over 180 days	**1,784**	16,668
Total	**3,038,505**	3,127,479

An ageing analysis of bills receivable as at the end of the Reporting Period, based on the billing date, is as follows:

	2025	2024
	RMB'000	*RMB'000*
Within 90 days	**18,119**	41,441
91 days to 180 days	**3,893**	843
Total	**22,012**	42,284

The Group applies the simplified approach to providing for expected credit losses prescribed by HKFRS 9, which permits the use of the lifetime expected credit loss provision for all trade receivables.

To measure the expected credit losses for trade receivables, trade receivables have been grouped based on shared credit risk characteristics and the ageing.

The movements in the loss allowance for impairment of trade receivables are as follows:

	2025	2024
	RMB'000	*RMB'000*
At beginning of year	**12,425**	30,604
Reversal of impairment *(Note 6)*	**(831)**	(18,179)
At end of year	**11,594**	12,425

11. CASH AND BANK BALANCES

	2025	2024
	RMB'000	*RMB'000*
Cash and bank balances, unrestricted	**2,941,080**	2,101,651
Time deposits with original maturity of less than three months when acquired	**467,839**	221,050
Time deposits with original maturity of over three months when acquired *(note (a))*	**28,139,749**	20,298,865
Cash and bank balances	**31,548,668**	22,621,566

Note:

(a) The above investments represent time deposits with initial terms of over three months when acquired (including three months) issued by commercial banks with annual return rates ranging from 1.35% to 4.50% (2024: 3.30% to 5.89%). None of these investments are past due or impaired. None of these deposits are pledged.

12. TRADE PAYABLES

	2025	2024
	RMB'000	*RMB'000*
Trade payables	**334,314**	217,851
Total	**334,314**	217,851

An ageing analysis of the trade payables as at the end of the Reporting Period, based on the invoice date, is as follows:

	2025	2024
	RMB'000	*RMB'000*
Within 90 days	**333,883**	211,421
91 days to 180 days	**29**	709
181 days to 1 year	**105**	2,055
Over 1 year	**297**	3,666
Total	**334,314**	217,851

The trade payables are non-interest-bearing and are normally settled on 90-day terms.

13. OTHER PAYABLES AND ACCRUALS

	2025	2024
	RMB'000	*RMB'000*
Accrued expenses	**1,617,387**	1,490,774
Staff payroll, welfare and bonus payables	**440,270**	438,431
Payables for purchase of items of property, plant and equipment	**29,267**	27,481
Other tax payables	**102,808**	160,546
Other payables	**372,847**	237,359
Total	**2,562,579**	2,354,591

14. SHARE CAPITAL

	2025	2024
	RMB	*RMB*
Issued and paid:		
6,055,150,070 shares of HK$0.00001 each (31 December 2024: 5,935,650,070 shares of HK$0.00001)	**53,379**	52,286

A summary of movements in the Company's share capital is as follows:

	Number of shares in issue	**Share capital** *RMB*
At 1 January 2025	5,935,650,070	52,286
Issue of shares pursuant to the Group's RSU Scheme adopted on 27 May 2019, HK$0.00001 each *(note (a))*	11,500,000	107
New issue of ordinary shares by placing on 27 August 2025, HK$0.00001 each *(note (b))*	108,000,000	986
At 31 December 2025	6,055,150,070	53,379

Notes:

(a) On 22 April 2025, the Company issued 11,500,000 new ordinary shares to Computershare Hong Kong Trustees Limited (the "**RSU Trustee**") at the price of HK$2.9595 per share, pursuant to the terms of the RSU Scheme approved and adopted on 27 May 2019 for vesting of the restricted share units.

(b) On 27 August 2025, the Company issued 108,000,000 new ordinary shares at the price of HK$36.30 per share by placing.

EVENTS AFTER THE REPORTING PERIOD

In January 2026, Ameile (Aumolertinib Mesylate Tablets) was granted drug registration approval by the NMPA, approving the addition of an indication: Ameile in combination with pemetrexed and platinum based chemotherapy to be used as the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) mutations. This is the fifth indication of Ameile which has been approved.

On February 3, 2026, the Company successfully completed the issuance and listing of HK$4,680 million zero-coupon convertible bonds due in 2033 to professional investors only (the "**Bonds**"). On February 4, 2026, the Bonds were admitted to trading and listing on the Vienna MTF operated by the Vienna Stock Exchange, effective February 6, 2026. The Bonds have been offered and sold to no less than six independent placees (who are professional investors). Assuming full conversion of the Bonds at the initial conversion price of HK$57.39 per Share, the Bonds will be convertible into 81,547,308 Shares (with aggregate nominal value of approximately HK$815). The closing price per share as quoted on the Stock Exchange on January 26, 2026, being the date on which the initial conversion price was determined, was HK$40.24. The Directors consider the issue of Bonds represents an opportunity to raise capital for the Company while broadening the shareholder base and capital base of the Company and to obtain immediate funding for further business expansion.

The net proceeds from the Bonds were approximately HK$4,640 million, representing a net issue price of approximately HK$56.90 per conversion share based on the initial conversion price. As disclosed in the announcements of the Company dated January 27, 2026 and February 3, 2026, the Company intends to apply the net proceeds from the issuance of the Bonds in the following manner:

(a) approximately 65% on drug R&D and in-licensing:

The intended use of such net proceeds includes (i) funding of the R&D of the Group's innovative medicine pipeline across oncology, CNS, metabolic and autoimmune diseases, covering preclinical to late-stage clinical programs; and (ii) supporting selective in-licensing projects for innovative medicines and R&D platforms to enrich the Group's product portfolio and facilitate near-term commercialization in the PRC.

The Group's progress in advancing multiple innovative programs into mid-to-late stage clinical development demonstrates its continued commitment and increased investment in clinical R&D, while also benefiting from a versatile early-stage preclinical pipeline supported by sustained investment. Between 2019 and 2025, the Group has, on average, advanced approximately eight innovative preclinical or in-licensing candidates into clinical trials per year, demonstrating a productive internal R&D and business development engine.

The Group plans to further increase investment in preclinical R&D in 2026 and beyond, with a focus on strengthening pipeline depth and ensuring a sustainable flow of high-quality innovative candidates from preclinical research into clinical development, taking into account global development potential for selected programs. For selected high-potential newly developed programs, the Group has incorporated, and will continue to incorporate, early consideration of global development planning, with the aim of strengthening international competitiveness and enhancing future partnering potential, subject to program-specific development considerations.

While the Group continues to advance selected innovative programs with a view to its mid-to-long-term development, it also adopts a pragmatic approach in the near term to accelerate the enrichment of its pipeline with products that have clear commercialization potential in the PRC. In this regard, the Company has entered into over 10 in-licensed collaboration projects to broaden its product portfolio in China, and expects to continue pursuing such collaborations as appropriate to support near-term commercialization and growth. Pursuant to the existing exclusive licensing or collaboration agreements, the Company is required to pay milestone payments to the licensors upon the achievement of specified development, regulatory or commercialization milestones. In particular, R&D and registration milestone payments are payable prior to the commercialization of the in-licensed drugs or technology platforms.

(b) approximately 25% on the construction of new R&D centers and production lines, and the upgrade of existing R&D and production facilities:

The intended use of such net proceeds includes the construction and expansion of innovative medicine R&D centers and laboratories, the construction of new production lines, and the upgrading and enhancement of existing R&D laboratories and production facilities.

The Company intends to apply part of the net proceeds to, among others, the Phase II construction of the Company's global R&D headquarters project in Pudong, Shanghai, which is planned to commence in 2028 and is expected to be of a comparable scale to the ongoing Phase I construction which commenced in 2024. The new headquarters is designed to accommodate advanced R&D infrastructure and will encompass facilities including biological laboratories and pilot-scale units, chemical R&D laboratories, R&D offices and supporting utilities. The project is intended to establish an integrated global platform for innovative medicine R&D technologies and modalities, including ADC, artificial intelligence, proteolysis targeting chimera (PROTAC) and peptide drug, and to undertake global R&D management functions, serving as a key hub for the Group's scientific research and technological development.

The Company plans to continue upgrading and enhancing its existing R&D process development and clinical-supply production facilities and related equipment, with a focus on supporting the development, scale-up and clinical supply of products based on such new modalities. In this regard, the Company intends to utilize part of the proceeds to support the upgrading and improvement of its existing R&D centers located in the PRC, including those in Shanghai, Changzhou and Lianyungang, subject to further refinement of the scope and implementation plan.

The Company also intends to construct new commercial production lines to expand its manufacturing capacity, with a view to further advancing the integration of informatization and industrialization (the "**Two Integrations**"). In this connection, the Company plans to deploy intelligent and digitalized manufacturing and testing equipment to continuously enhance the smart manufacturing capabilities of its industrial base.

In light of the anticipated commercialization of products based on new technology modalities from 2027 and beyond, particularly in therapeutic areas such as oncology, metabolic diseases and immunology, the Company considers it necessary to establish additional production lines and to strengthen manufacturing capabilities aligned with such modalities. The Company will also carry out forward-looking capacity planning and phased capacity expansion investments to support the expected growth in commercial supply following product launches, while maintaining flexibility to adjust capacity deployment based on actual market demand and product uptake.

(c) approximately 10% for working capital and other general corporate purposes:

The intended use of such net proceeds includes supplier payments, employee compensation, drug production to replenish the Company's inventory, and other routine operational expenditures, which are subject to our actual needs and market conditions at the relevant time.

As at the date of this announcement, approximately HK$193.50 million of the net proceeds as stated above has been utilized in accordance with the purposes stated above while the remaining proceeds remain unutilized. The net proceeds will be used in accordance with the intended purposes previously disclosed by the Company, and the Company will provide further update according to the requirements of the Listing Rules. The net proceeds from the Bonds are expected to be fully utilized by 2031. Such expected time frame is based on the Board's best estimation, and may be subject to change based on factors such as the future development of the Company, the market conditions, status of regulatory approval, acquisition of qualifications and licenses as well as business conditions. For details of the issuance of the Bonds, please refer to the announcements of the Company dated January 27, 2026 and February 3, 2026.

In February 2026, Aumolertinib Mesylate Tablets, marketed as Ameile (阿美樂®) in China and Aumseqa® outside China, the Group's innovative medicine, has been approved in the European Union as monotherapy for: (i) the first-line treatment of adult patients with advanced NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations; and (ii) the treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC. The approval by the European Commission (EC) follows the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the EMA.

In February 2026, the NDA of the Group's innovative medicine Dalmelitinib Mesylate Tablets in combination with Aumolertinib Mesylate Tablets (Ameile 阿美樂®), has been accepted by the NMPA for the treatment of patients with locally advanced or metastatic EGFR mutation-positive NSCLC whose tumors have MET amplification after prior EGFR TKI therapy.

In March 2026, HS-10587 tablets, a Category 1 innovative medicine self-developed by the Group, has obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for MTAP-deleted advanced solid tumors.

In March 2026, HS-20152 injection, a Category 1 innovative medicine self-developed by the Group, has obtained a clinical trial approval issued by the NMPA, which is intended to be investigated in clinical trials for PNH.

In March 2026, the Group's innovative medicine XINYUE (昕越®) (Inebilizumab Injection) has been granted drug registration approval by the NMPA, approving the addition of an indication: the product is used in combination with conventional therapeutic drugs for the treatment of adult patients with gMG who are positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. This is the third indication of XINYUE which has been approved.

Save as disclosed above, there is no material event affecting the Company during the period from December 31, 2025 to the date of this announcement.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company's corporate governance practices are based on the principles and code provisions as set out in the Corporate Governance Code (the "**CG Code**") contained in Appendix C1 to the Listing Rules and the Company has adopted the CG Code as its own code of corporate governance.

The Board is of the view that the Company has complied with all the code provisions in effect as set out in Part 2 of the CG Code during the Reporting Period, save for code provision C.2.1 of the CG Code.

Code Provision C.2.1

Code provision C.2.1 of the CG Code states that the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. The Company has appointed Ms. Zhong Huijuan ("**Ms. Zhong**") as both the chairlady and the chief executive officer of the Company. Due to the nature and the extent of the Group's operations and Ms. Zhong's in-depth knowledge and experience in the PRC pharmaceutical industry, the Board considers that the balance of power and authority under the present arrangement is not impaired and this structure will enable the Company to make and implement decisions promptly and effectively. The Board will continue to review and consider splitting the roles of chairlady of the Board and the chief executive officer of the Company at a time when it is appropriate by taking into account the circumstances of the Group as a whole.

The Board will periodically review and enhance its corporate governance practices to ensure that the Company continues to meet the requirements of the CG Code.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted its own code of conduct regarding securities transactions of the Company by Directors (the "**Company Code**") on terms no less exacting than the required standard set out in the Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix C3 to the Listing Rules. Specific enquiry has been made to all Directors by the Company and all Directors confirmed that they have complied with the Company Code during the Reporting Period.

AUDIT COMMITTEE

The Board has established an audit committee (the "**Audit Committee**") with written terms of reference in compliance with Rule 3.21 of the Listing Rules and paragraph D.3 of Part 2 of the CG Code. The Audit Committee consists of four independent non-executive Directors, namely Mr. Chan Charles Sheung Wai (chairman of the Audit Committee), Mr. Lin Guoqiang, Ms. Yang Dongtao and Mr. Yan Jia.

The Audit Committee and the external auditor, Ernst & Young, have reviewed the audited results of the Group for the year ended December 31, 2025. The Audit Committee has also reviewed the accounting principles and practices adopted by the Group and its internal controls and financial reporting matters.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the year ended December 31, 2025, neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares) (as defined under the Listing Rules). As at December 31, 2025, no treasury shares (as defined under the Listing Rules) were held by the Company.

FINAL DIVIDEND

The Board recommends a final dividend of HK$20.00 cents per share for the year ended December 31, 2025 (2024: HK$13.53 cents). Subject to the approval of the shareholders of the Company ("**Shareholders**") at the forthcoming annual general meeting of the Company (the "**AGM**"), the proposed final dividend will be payable on Friday, July 24, 2026 to Shareholders whose names appear on the register of members of the Company at the close of business on Thursday, July 9, 2026, being the record date. Together with an interim dividend of HK$23.16 cents per share, the full-year dividend for 2025 amounted to HK$43.16 cents per share. All treasury shares and repurchased shares pending cancellation, if any, will not receive the proposed final dividend.

CLOSURE OF REGISTER OF MEMBERS

In order to ascertain the Shareholders' entitlements to the proposed final dividend (subject to the approval by the Shareholders at the AGM), the register of members of the Company will be closed from Tuesday, July 7, 2026 to Thursday, July 9, 2026, both days inclusive, during which period no transfer of shares will be registered. In order to qualify for the proposed final dividend, all share transfer documents accompanied by the relevant share certificates must be lodged for registration with the Company's Hong Kong branch share registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not later than 4:30 p.m. on Monday, July 6, 2026.

USE OF PROCEEDS FROM PREVIOUS FUNDRAISING ACTIVITIES AS AT DECEMBER 31, 2025

Use of Proceeds from Issuance of Convertible Bonds

In January 2021, the Company successfully completed the issuance and listing of US$600 million zero-coupon convertible bonds due in 2026 to professional investors only. The net proceeds from the bonds were approximately US$595.65 million. In December 2022, the Company repurchased bonds with an aggregate principal amount of US$4 million. In January 2024, the Company redeemed the outstanding convertible bonds in the aggregate principal amount of US$590,622,000. On January 22, 2026, being the maturity date of the convertible bonds, the Company redeemed the outstanding principal amount of US$5,378,000.

As at December 31, 2023, US$591.65 million was utilized and the net proceeds had been fully utilized. Such proceeds were primarily used for R&D expenditure (including but not limited to allocating funding to clinical trials for innovative medicines, innovative medicines development and/or in-license opportunities) as well as upgrading and expanding manufacturing facilities (including R&D facilities) and procuring equipment for its production facilities, in line with the purpose previously disclosed by the Company. For details of the use of proceeds, please refer to the section headed "Use of Proceeds from Issuance of Convertible Bonds" in the 2023 annual report and 2024 annual report of the Company.

Use of Proceeds from the Placing

On August 20, 2025, the Company entered into a placing agreement with Citigroup Global Markets Asia Limited, Citigroup Global Markets Limited and Morgan Stanley Asia Limited (in alphabetical order), pursuant to which Citigroup Global Markets Limited and Morgan Stanley Asia Limited (together, the "**Placing Agents**") agreed to place 108,000,000 ordinary shares (with an aggregate nominal value of HK$1,080) in the Company, or, failing which, to purchase themselves on a fully underwritten basis, to not fewer than six placees who are professional, institutional or other investors selected and procured by the Placing Agents and whose ultimate beneficial owners are independent third parties (the "**Placing**"). The Placing price was HK$36.30 per share. The closing price per share as quoted on the Stock Exchange on August 19, 2025, being the date on which the Placing price was fixed, was HK$38.82. The Directors consider that the Placing represents an opportunity to raise capital for the business development of the Group and to broaden the Shareholder base of the Company. For further details of the Placing, please refer to the announcement of the Company dated August 20, 2025.

The net proceeds from the Placing (after deducting the Placing commission, levies and trading fee) were approximately HK$3,896.54 million, which have been and will be utilized as follows:

(i) approximately 65% for (a) the R&D of new innovative medicines in therapeutic areas including oncology, autoimmune, CNS and metabolic diseases, and (b) the in-licensing for innovative medicines and innovative technology platforms. Proceeds is mainly used for the later-stage clinical R&D activities of the Group's existing programs.

(ii) approximately 25% for (a) the construction of new innovative medicine production facilities and R&D laboratories, and (b) the upgrade of the Group's existing R&D laboratories and production facilities. Part of the proceeds has been applied to Phase I construction of the Company's Shanghai global R&D headquarters project.

(iii) approximately 10% for working capital and other general corporate purposes.

On this basis, the net price per Placing share was approximately HK$36.08. As at December 31, 2025, net proceeds of approximately HK$436 million was utilized and approximately HK$3,461 million remains unutilized. The net proceeds were used, and the remaining proceeds will be used, according to the intended purposes and timeline previously disclosed by the Company. As at December 31, 2025, the net proceeds utilized by the Group were as follows:

Purpose	Percentage of the total amount	Net proceeds (HK$100 million)	Utilized from the issuance date to December 31, 2025 (HK$100 million)	Unutilized as at December 31, 2025 (HK$100 million)	Expected time frame
(i) (a) the R&D of new innovative medicines in therapeutic areas including oncology, autoimmune, CNS and metabolic diseases, and (b) the in-licensing for innovative medicines and innovative technology platforms	65%	25.32751	3.96799	21.35952	The balance is expected to be fully utilized by 2031
(ii) (a) the construction of new innovative medicine production facilities and R&D laboratories, and (b) the upgrade of the Group's existing R&D laboratories and production facilities	25%	9.74135	0.38889	9.35246	The balance is expected to be fully utilized by 2031
(iii) working capital and other general corporate purposes	10%	3.89654	-	3.89654	The balance is expected to be fully utilized by 2031
Total	100%	38.96540	4.35688	34.60852	

To the best knowledge of the Directors, there has neither been any material change nor delay in the use of proceeds during the year ended December 31, 2025.

PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT AND ANNUAL REPORT

This announcement is published on the websites of The Stock Exchange of Hong Kong Limited (**www.hkexnews.hk**) and the Company (**www.hspharm.com**). The annual report for the year ended December 31, 2025 of the Company and the notice of the AGM setting out, among others, proposed date of the AGM, the period of closure of register of members and the record date for determining the entitlement of the attendance of the AGM will be available on the same websites in due course.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, March 29, 2026

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive Director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive Directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai, Ms. Yang Dongtao and Mr. Yan Jia as independent non-executive Directors.

* *For identification purposes only*